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Abstract
Background The control of muscle size is an essential feature of health. Indeed, skeletal muscle atrophy leads to reduced
strength, poor quality of life, and metabolic disturbances. Consequently, strategies aiming to attenuate muscle wasting and
to promote muscle growth during various (pathological) physiological states like sarcopenia, immobilization, malnutrition,
or cachexia are needed to address this extensive health issue. In this study, we tested the effects of urolithin B, an
ellagitannin-derived metabolite, on skeletal muscle growth.
Methods C2C12 myotubes were treated with 15 μM of urolithin B for 24 h. For in vivo experiments, mice were implanted
with mini-osmotic pumps delivering continuously 10 μg/day of urolithin B during 28 days. Muscle atrophy was studied in mice
with a sciatic nerve denervation receiving urolithin B by the same way.
Results Our experiments reveal that urolithin B enhances the growth and differentiation of C2C12 myotubes by increasing
protein synthesis and repressing the ubiquitin–proteasome pathway. Genetic and pharmacological arguments support an
implication of the androgen receptor. Signalling analyses suggest a crosstalk between the androgen receptor and the mTORC1
pathway, possibly via AMPK. In vivo experiments conﬁrm that urolithin B induces muscle hypertrophy in mice and reduces
muscle atrophy after the sciatic nerve section.
Conclusions This study highlights the potential usefulness of urolithin B for the treatment of muscle mass loss associated
with various (pathological) physiological states.
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Introduction
Skeletal muscle represents about 45% of body mass in young
male adults. Owing to its capacity to generate strength,
muscle is responsible for mobility, respiration, and posture
maintenance. Muscles also play a major role in metabolism
regulation by consuming large amount of glucose and
lipids, particularly during exercise. Several physiological and
physiopathological conditions like ageing, immobilization,
chronic hypoxia, cancer, or sepsis disrupt the equilibrium
between muscle protein synthesis and breakdown and
lead to muscle atrophy and consequently, to strength
loss and metabolic disturbances.1 Therefore, pursuing strate-
gies to reduce muscle atrophy is a major challenge for
researchers.
Urolithins are ellagitannin or ellagic acid metabolites, with
different phenolic hydroxylation patterns, produced by the
microﬂora in the gastrointestinal tract after the ingestion of
some fruits.2 The ﬁrst product of ellagic acid catabolism is
urolithin D, and successive loss of hydroxy groups result in
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the formation of urolithins C, A, and B.3 All mammals seem
able to produce urolithins from ellagitannins found in food.4,5
In healthy humans, urolithins A and B are most abundant.5,6
Urolithin A is the most reported analogue due to its anti-
oxidative and anti-inﬂammatory properties in various
tissues.7–10 Supplementing the diet with ellagitannins attenu-
ates muscle damage experienced during strenuous exer-
cise,11 and ellagitannin-rich pomegranate extract protects
muscle against stresses induced by a high-fat diet.12 Never-
theless, because of the low bioavailability of ellagitannins,13
it is likely that ellagitannin-derived metabolites are responsi-
ble for the reported effects. Therefore, it seems important to
characterize the effects of urolithins themselves. Doing this,
we incidentally observed that myotubes in culture were big-
ger after incubation with urolithin B and thereby discovered
a new characteristic of urolithin B. Therefore, we sought to
describe this phenomenon further and to understand the
underlying molecular mechanisms.
In this study, we report that urolithin B enhances
myotubes growth and differentiation, induces muscle cell
hypertrophy, and inhibits the ubiquitin–proteasome pathway
both in vitro and in vivo.
Results
Urolithin B enhances differentiation of C2C12
myotubes
We incubated myotubes with different urolithin concentra-
tions during 24 h and evaluated the impact of each treat-
ment on their size (see Supporting Information, Figure
S1A–S1D). The latter was never affected in the presence of
urolithin A, whereas low doses of urolithin B increased the
diameter of myotubes. The most effective concentration
was identiﬁed at 15 μM as the effect disappeared with
higher doses (see Supporting Information, Figure S1A and
S1B). This concentration was used for the experiments
reported in Figure 1, which conﬁrms the anabolic properties
of urolithin B in myotubes (Figure 1A and 1B). The higher
fusion index (+16.3%) indicated an enhanced fusion
capability of the cells (Figure 1C). The up-regulation of the
myogenic factor myogenin (P = 0.06) and the marker of differ-
entiation, desmin14 (P < 0.05) after 5 days, conﬁrmed the
stimulation of cell differentiation in the presence of urolithin
B (Figure 1D and 1E).
Urolithin B stimulates protein synthesis in C2C12
myotubes by activating mTORC1 signalling
To test the hypothesis that urolithin B stimulates muscle
anabolism to induce hypertrophy, we investigated the
Akt/mTORC1 (protein kinase B/mammalian target of
rapamycin complex 1) pathway. When Akt is activated, it
phosphorylates the mTORC1 complex.1 4E-BP1, a repressor
of mRNA translation, is then phosphorylated and inactivated
by mTORC1.15 S6K1 is another downstream target of
mTORC1 that is a kinase for the ribosomal protein rpS6. The
phosphorylation state of S6K1 correlates with an increase in
translation of mRNA transcripts.1 Here, we did not detect
any change in the phosphorylation state of Akt with urolithin
B (Figure 1F). Nevertheless, the phosphorylation states of
mTOR, rpS6, and 4E-BP1 were higher, and rapamycin, a
well-known inhibitor of mTORC1,16 completely blunted the
effects (Figure 1G–1I). These results strongly suggest that
the mTORC1 pathway was activated independently of Akt in
response to urolithin B treatment.
We also analysed another regulator of mTORC1 activity,
that is, AMP-activated protein kinase (AMPK). Compatible
with a higher mTORC1 activity, AMPK was dephosphorylated
by 42.2% (Figure 1J). However, this regulation was neither
due to a modiﬁcation of adenine nucleotide concentrations
(see Supporitng Information, Figure S1E) nor to a reduction
in the phosphorylation state of the liver kinase B1, another
regulator of AMPK (see Supporting Information, Figure S1F).
Finally, we measured protein synthesis in myotubes using
the non-radioactive SUnSET method.17 Myotubes were
treated either with urolithin B (15 μM) or the vehicle
(DMSO), or rapamycin (40 nM) as a negative control, or insu-
lin (100 nM) as a positive control. As expected, compared
with untreated cells, puromycin incorporation was decreased
by about 11.2% after rapamycin incubation and increased by
61.5% after insulin incubation (Figure 1K and 1L). Urolithin B
up-regulated protein synthesis in myotubes by 96.1%
(P < 0.001 vs. control, Figure 1K and 1L). Here again, we
did not detect any difference in puromycin incorporation
with the same concentration of urolithin A, showing that
the two isoforms, urolithins B and A, do not induce the same
effects in muscle cells (see Supporting Information, Figure
S1G and S1H).
Collectively, these data indicate that urolithin B stimulates
protein synthesis in myotubes by an mTORC1-dependent
mechanism, possibly triggered by a decreased AMPK activity.
Urolithin B inhibits protein degradation by down-
regulating the ubiquitin–proteasome pathway
The signalling pathways regulating protein synthesis or degra-
dation are largely interconnected at the level of Akt1 or
mTORC1.18,19 The Akt/mTORC1 pathway regulates two pro-
teolytic systems in muscle cells, namely, the ubiquitin–
proteasome and the autophagy–lysosomal pathways. Akt
prevents the nuclear translocation of the forkhead box fac-
tors 1 and 3a (FoxO1 and 3a) by phosphorylating multiple
sites.20,21 FoxOs are among the major transcription factors
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Figure 1 Urolithin B (UroB) promotes growth and differentiation of C2C12 myotubes. (A) After 4 days of differentiation, C2C12 myotubes were treated
with UroB (15 μM) or vehicle DMSO (CTRL), for 24 h. Cells were then ﬁxed and immunostained with anti-desmin, nuclei were revealed by Hoechst
staining. Scale bar = 50 μm. (B) Mean diameter of the myotubes seen in (A). Histograms are means ± SEM for 10 assays. Independent cell cultures
were carried out in triplicate. At least 2000 myotubes were analysed for both treated and untreated cells. ***P< 0.001 vs. CTRL cells (Student’s t-test).
(C) Fusion index of myotubes seen in (A) from at least ﬁve independent cultures. Data are means ± SEM. ***P < 0.001 vs. CTRL cells (Student’s t-test).
(D–F, J) Quantiﬁcation and representative immunoblots of proteins, as indicated. Data are means ± SEM for at least three experiments. P-values were
determined by Student’s t-test. *P < 0.05 vs. CTRL. (G–I) Quantiﬁcation and representative immunoblots of proteins, as indicated. Data are
means ± SEM for at least three experiments. P-values were determined by Bonferroni post-hoc test. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. ve-
hicle (vh) CTRL;
$$$
P < 0.001 vs. rapamycin (Rapa, 40 nM) CTRL. (K) Representative image of WB analysis for puromycin and eEF2, a stable protein in
our samples. Insulin (Ins, 100 nM) was added as a positive control and rapamycin (40 nM) as a negative control. (L) Quantiﬁcation of the puromycin-
labelled peptides, expressed as a percentage of the values obtained in untreated CTRL cells. Data are means ± SEM. P-values were determined by one-
way analysis of variance with Bonferroni post-hoc test.*P < 0.05, **P < 0.01, and ***P < 0.001 vs. CTRL. See also Supporting Information Figure S1.
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regulating the expression of the muscle-speciﬁc ligases
MAFbx and MuRF1, which are induced during several situa-
tions of muscle atrophy.20,22 The phosphorylated form of
FoxO1 and 3a were not modiﬁed by urolithin B (Figure 2A
and 2B). Interestingly, we observed a signiﬁcant reduction
of the total form of FoxO3a (Figure 2C). Reverse transcription
quantitative PCR analysis also indicated that mRNA coding
FoxO1 and FoxO3, as well as the mRNA levels of ubiquitin
ligase MAFbx and MuRF1 were decreased by urolithin B
(Figure 2D). Immunoblotting using an anti-P4D1 antibody
revealed a lower amount of ubiquitinated proteins in treated
cells (22.1%, P < 0.05, Figure 2E and 2F). These results
strongly suggest a lower activity of the ubiquitin–proteasome
system in myotubes treated with urolithin B.
We also analysed whether urolithin B was capable of
repressing the autophagy–lysosomal pathway, which is
Figure 2 Urolithin B (UroB) down-regulates the ubiquitin–proteasome pathway. (A–C) Effect of UroB (15 μM) on phospho-FoxO1/FoxO3a and total
FoxO3a. eEF2 was used as a loading control on protein extracts from C2C12 myotubes collected after 24 h of UroB treatment. Data are means ± SEM
for at least three experiments. P-values were determined by Student’s t-test. **P < 0.01. (D) Effect of UroB (15 μM) on FoxO1, FoxO3a, MAFbx, and
MuRF1 mRNA levels, normalized to RPL19 mRNA, as assessed by quantitative PCR. Data are means ± SEM for at least three experiments. P-values were
determined by Student’s t-test. **P < 0.01 and ***P < 0.001 vs. CTRL. (E–F) Representative immunoblot for ubiquitinated protein and quantiﬁcation.
Data are means ± SEM for at least three experiments. P-values were determined by Student’s t-test. *P < 0.05 vs. CTRL. (G) Protein degradation quan-
tiﬁcation by 35S-labeling. Data are means ± SEM from three experiments. P-values were determined by Student’s t-test. ***P< 0.001 vs. CTRL. See also
Supporting Information Figure S2.
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another important proteolytic pathway in muscle regulated
by mTORC1 and FoxOs as well.23,24 No markers of autophagy
that we studied were changed in the presence of urolithin B.
As expected, insulin (100 nM) decreased both phospho-ULK1
(Ser757) and the ratio LC3bII/I. Inversely, rapamycin (40 nM)
and phosphate-buffered saline (PBS) increased them (see
Supporting Information, Figure S2A and S2B). Adding
urolithin B in all these conditions did not modify further the
autophagy markers. Moreover, autophagy-related gene
expression programme did seem to be affected as assessed
by unchanged Lc3b, p62, and Gabarapl1 mRNA (see
Supporting Information, Figure S2C).
As the ubiquitin–proteasome system seems to be regu-
lated by urolithin B, we next measured the protein degrada-
tion rate by dilution of 35S-methionine in myotubes and
found that urolithin B decreased it by 16.7% (P < 0.001,
Figure 2G).
Collectively, these results show that the faster growth of
myotubes in the presence of urolithin B is due to a higher
protein synthesis combined with a reduced activity of the
ubiquitin–proteasome system, independently of autophagy.
The anabolic effect of urolithin B is mediated by
the androgen receptor
Because previous studies highlighted a link between andro-
gen receptor (AR) and the mTORC1 pathway25 and provided
evidence for anti-aromatase properties of urolithin B in
breast cancer cells,26 we hypothesized that urolithin B
induces hypertrophy in myogenic cells through the activation
of AR. Thus, we inactivated AR genetically by using a set of
speciﬁc small interfering RNA (siRNAs) and pharmacologically
by using bicalutamide. The siRNA transfection repressed the
mRNA level of AR by 72.4%, and urolithin B treatment had
no effect on this level (see Supporting Information, Figure
S3A). In comparison with the scramble condition, the genetic
repression of AR completely abolished the enhancement of
myotube size induced by urolithin B (Figure 3A and 3B). Inter-
estingly, siRNAs totally blocked the hypertrophy induced by
both testosterone and urolithin B, providing the ﬁrst evidence
for the implication of AR in the enhanced growth of
myotubes in the presence of urolithin B. To ensure that the
transfection still allowed hypertrophy induced by other
molecules targeting other receptors, we successfully
repeated the same experiment with insulin (see Supporting
Information, Figure S3B and S3C).
To conﬁrm our results acquired on the basis of a genetic
repression model, we used bicalutamide (5 μM), a pharma-
cological inhibitor of AR.27 As anticipated, bicalutamide to-
tally repressed the increase in myotube size induced by
testosterone and urolithin B (Figure 3C and 3D). The inhibi-
tion of AR by bicalutamide also prevented the increase of
phosphorylated mTOR and rpS6 induced by urolithin B
(Figure 3E and 3F). In agreement with the idea that AMPK af-
fects urolithin B-induced signalling, we did not observe any
change in the AMPK phosphorylation state when cells were
simultaneously treated with bicalutamide and urolithin B
(Figure 3G). This also suggests that AMPK could be a link
between AR and mTORC1.
To provide more evidence in favour of the activation of AR
upon urolithin B treatment, we transfected C2C12 cells with a
dual-luciferase reporter gene under the control of AR pro-
moter. A higher activity of AR promoter when the myotubes
were incubated with urolithin B (+90.6%, P < 0.001, Figure
3H) or testosterone (+49.6%, P < 0.05, Figure 3H) was ob-
served. No synergic effects were observed with simultaneous
treatment of urolithin B and testosterone compared with
urolithin B alone, suggesting a saturation process.
To ensure the speciﬁcity of AR activation, we examined
whether the oestrogen receptor 1 (ER1) also mediated the
hypertrophic effects of urolithin B. Thus, we inactivated ER1
with a set of speciﬁc siRNAs, which also induced a decreased
diameter of the myotubes under control conditions (see
Supporting Information, Figure S3D and S3E). Even though
the transfection of siRNA against ER1 receptor induced a
decrease of myotubes diameter, we still observed the effects
of testosterone and urolithin B on myotube size, showing that
ER1 is probably not involved.
Collectively, our results provide strong evidence in favour
of the implication of AR in the enhancement of C2C12
myotubes growth induced by urolithin B.
Urolithin B-induced skeletal muscle hypertrophy in
mice
To conﬁrm the aforementioned results in an animal model,
we implanted mini-osmotic pumps delivering urolithin B
(10 μg/day) in male mice. In a preliminary experiment, we
found that such a perfusion rate led to a plasma concentra-
tion of urolithin B of 1.3 μM, which is very compatible with
the concentration of urolithin A or B found in the plasma of
rodents fed with ellagitannin-rich extracts.28 During the ﬁrst
3 weeks of treatment, the body weight gain was higher in
mice receiving urolithin B, but this difference reached a
plateau during the 4th week (Figure 4A). At that time, the
animals were sacriﬁced, and the muscles were collected.
The weight of tibialis anterior (TIB), soleus (SOL), and quadri-
ceps muscles (QUA) was higher in mice receiving urolithin B
(Figure 4B), while the weight of epididymal adipose tissue
(EpiD) and testis was lower (Figure 4B). Cross-sectional area
of TIB muscle ﬁbres was 11.9% larger in mice treated with
urolithin B than in controls (Figure 4C). Moreover, the ﬁbres
distribution analysis showed a shift towards a higher percent-
age of large ﬁbres (Figure 4D). In agreement with the results
from the cellular model, the phosphorylation state of Akt
remained unchanged in the presence of urolithin B, whereas
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Figure 3 Implication of the androgen receptor (AR) in myotubes hypertrophy induced by urolithin B (UroB). (A–G) The androgen receptor was
inactivated in C2C12 myotubes by siRNA (siRNA AR) or by bicalutaimide (Bic, 5 μM). Myotubes were then treated, during 24 h, with either vehicle
DMSO or 15 μM UroB or 100 nM testosterone (T) used as a positive control. (A) Representative immunoﬂuorescence images of myotubes, transfected
with siRNA targeting the AR or the scramble vector (Scr) and stained with anti-desmin antibody and Hoescht. (B) Quantiﬁcation of myotube diameter.
Data are means ± SEM from three experiments, each with >300 myotubes measured per condition. P-values were determined by Bonferroni post-hoc
test. **P < 0.01 and ***P < 0.001 vs. Scr CTRL;
$$$
P < 0.001 vs. Scr UroB;
£££
P < 0.001 vs. Scr T. (C) Representative immunoﬂuorescence images of
myotubes, treated with bicalutamide or vehicle DMSO (vh) and stained with anti-desmin antibody and Hoechst. (D) Quantiﬁcation of myotube diam-
eter. Data are means ± SEM from three experiments, each with >300 myotubes measured per condition. **P < 0.01 and ***P < 0.001 vs. vh CTRL; $$
$
P < 0.001 vs. vh UroB;
££
P < 0.01 vs. vh T. (E–G) Quantiﬁcation and representative immunoblot for phosphorylated and total mTOR, phosphorylated
rpS6 and eEF2, and phosphorylated and total AMPK, as indicated. Data are means ± SEM from at least three experiments. P-values were determined by
Bonferroni post-hoc test. *P < 0.05 vs. CTRL vh group. (H) Quantiﬁcation of AR promotor activity measured with a dual-luciferase assay. Myoblasts
were transfected by nucleofection with dual reporter genes, differentiated and then treated the 4th day of differentiation with 50 μM UroB,
500 nM T, or both (UroB + T), during 24 h. Fireﬂy luciferase activity was subsequently normalized against renilla luciferase reporter. *P < 0.05,
**P < 0.01, and ***P < 0.001 vs. CTRL. P-values were determined by one-way analysis of variance with Bonferroni post-hoc test. See also Supporting
Information Figure S3.
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Figure 4 Urolithin B (UroB) induces skeletal muscle hypertrophy in mice. Twelve-week-old male mice were implanted with a mini-osmotic pump con-
taining UroB or the control vector DMSO (CTRL). The pumps delivered 10 μg of UroB per day during 28 days. Thirty minutes before sacriﬁce, mice were
treated by intraperitoneal injection with puromycin reagent for measuring protein synthesis. (A) Body weight gain throughout the duration of exper-
iment. Data are means ± SEM from six mice per condition. P-values were determined with Student’s t-test on body weight differences. *P < 0.05 and
**P < 0.01. (B) Weights of tibialis anterior (TIB), extensor digitorum longus (EDL), gastrocnemius (GAS), soleus (SOL), and quadriceps (QUA) muscles
and weights of epididymal adipose tissue (EpiD) and testis. Data are means ± SEM from six mice per condition. P-values were determined with Stu-
dent’s t-test. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. CTRL. (C) Azorubine staining of TIB sections was used to quantify the relative cross-sectional
area. Data are means ± SEM from three mice per condition. *P < 0.05 vs. CTRL. (D) Fibre size distribution. Data are expressed as the percentage of the
total number of measured ﬁbres. Data are means ± SEM. P-values were determined with Student’s t-test. *P < 0.05 and **P < 0.01 vs. CTRL group.
(E–F) Representative immunoblot and quantiﬁcation for phosphorylated and total Akt, phosphorylated FoxO1/FoxO3a and total FoxO3a, phosphory-
lated and total mTOR, phosphorylated and total rpS6, and eEF2 in TIB muscle. In each TIB muscle, the ratio of phosphorylated protein on total protein
was calculated (each one was previously normalized to the level of the stable protein eEF2). Data are means ± SEM from six mice per condition.
P-values were determined with Student’s t-test. *P < 0.05 and **P < 0.01 vs. CTRL group. (G) Representative image of WB analysis for puromycin
and the stable protein eEF2. (H) Quantiﬁcation of the puromycin-labelled peptides in TIB muscle expressed as a percentage of the values obtained
in the CRTL group. Data are means ± SEM from six mice per condition. P-values were determined with Student’s t-test. **P < 0.01 vs. CTRL group.
(I) Plasma testosterone level in CTRL and UroB groups. See also Supporting Information Figure S4.
Urolithin B as regulator of skeletal muscle mass 7
Journal of Cachexia, Sarcopenia and Muscle 2017
DOI: 10.1002/jcsm.12190
the phosphorylation levels of mTOR and rpS6 were higher in
TIB muscle (Figure 4E and 4F). Although the body weight gain
showed a clear levelling-off, muscle protein synthesis was still
higher after 4 weeks of treatment with urolithin B as revealed
by puromycin incorporation (P < 0.01, Figure 4G and 4H in
TIB muscle, and see Supporting Information, Figure S4 in
SOL muscle). Finally, the muscle hypertrophy due to urolithin
B treatment did not seem related to plasma testosterone
levels as the latter was not affected (Figure 4I).
These results conﬁrm the in vitro data and show that
urolithin B increases muscle protein synthesis by a mecha-
nism dependent upon mTORC1 but independent of plasma
testosterone concentration.
Urolithin B reduces the loss of muscle weight
induced by denervation
As urolithin B induces muscle hypertrophy, we hypothesized
that this compound could have a protective effect during at-
rophy. Female mice were denervated by transecting the left
sciatic nerve and were simultaneously implanted with a
mini-osmotic pump delivering urolithin B (10 μg/day). After
7 days, the ratio denervated/innervated muscle weight was
higher for TIB (P < 0.05), EDL (extensor digitorum longus,
P < 0.05), SOL (P < 0.001), and QUA (P < 0.01) muscles of
animals treated with urolithin B compared with untreated an-
imals (Figure 5A). This ratio was not different in gastrocne-
mius (GAS) muscle. In order to understand the mechanisms
leading to the protective effects of urolithin B, we performed
histological and biochemical analyses in the TIB muscle.
Urolithin B prevented the decrease in the cross-section area
of the ﬁbres of denervated TIB muscles, as observed with
azorubine staining (Figure 5B and 5C). In fact, denervation in-
duced a shift towards the left of the distribution of the mus-
cle ﬁbre cross-section areas in mice treated with the vehicle,
whereas this shift was less pronounced in animals treated
with urolithin B (Figure 5D). Collectively, these data indicate
that urolithin B reduces denervation-induced muscle atrophy.
To determine the molecular mechanisms responsible for
denervation-induced muscle atrophy and protection by
urolithin B, we analysed the major markers involved in signal-
ling pathways controlling protein degradation after 3 days of
denervation. We observed signiﬁcant increases in FoxO1 and
FoxO3, ubiquitin ligases MAFbx and MuRF1, and myostatin
(growth factor reducing muscle mass29) mRNA levels in de-
nervated CTRL TIB compared with innervated CTRL TIB
(Figure 5F). Interestingly, these increases were reduced in de-
nervated urolithin B TIB compared with innervated urolithin
B TIB (Figure 5F). As expected from the previous results, the to-
tal form of FoxO3a was signiﬁcantly increased in CTRL muscle
after denervation, but not in urolithin B-denervated muscle
(see Supporting Information, Figure S5A). The phosphorylation
levels of FoxO1/FoxO3a or Akt were not affected under any of
the conditions (see Supporting Information, Figure S5B and
S5C). The amount of ubiquitinated proteins was signiﬁcantly
increased by denervation in CTRL muscle (P < 0.01), whereas
it remained unchanged in urolithin B-denervated muscle (Fig-
ure 5G and 5H). In denervated muscles of animals receiving
urolithin B, the ratio of phosphorylated AMPK on total AMPK
was reduced in comparison with mice receiving the vehicle
(see Supporting Information, Figure S5D). The phosphoryla-
tion state of mTOR (Ser2448) and rpS6 were increased in
denervated CTRL mice, whereas this increase was not
signiﬁcant between the two groups having received urolithin
B (see Supporting Information, Figure S5E–S5F).
Recently, urolithin B was identiﬁed as an inhibitor of
aromatase26 and thereby the conversion of testosterone into
estradiol. In agreement with this study, we observed a lower
level of aromatase in animals having received urolithin B (see
Supporting Information, Figure S5G and S5H). To assess the
impact of low aromatase levels on the androgen status of
the animals, we measured plasma testosterone. Contrary to
our hypothesis, plasma testosterone was decreased after
3 days (P < 0.001 vs. CTRL mice) and unchanged after 7 days
of treatment with urolithin B (Figure 5E), suggesting that the
inhibition of aromatase is likely not the major molecular
event in the regulation of muscle mass induced by urolithin B.
Discussion
Recent studies highlighted that some small natural molecules
found in plants or fruits might be used in the treatment or
prevention of skeletal muscle atrophy.30–32 Here, we demon-
strate that urolithin B, a small molecule generated in the in-
testine after the ingestion of fruits containing ellagitannins,
induces muscle hypertrophy both in vitro and in vivo. This
hypertrophy is related to a signiﬁcant increase in protein
synthesis rate and higher phosphorylations of mTOR and its
downstream target rpS6. These effects on cell growth are
not induced by urolithin A (Figure S1), supporting the speci-
ﬁcity of action of urolithins A and B, even if they differ by only
a hydroxyl group. Urolithin B also decreases protein degrada-
tion, through a down-regulation of the ubiquitin–proteasome
pathway. The mechanisms of action seem to be mediated by
the AR. Blockage of this receptor by a siRNA or a pharmaco-
logic agent totally prevents the effect of urolithin B. This is
conﬁrmed by dual-luciferase assays showing that urolithin B
targets the AR in C2C12 myotubes.
Our results are consistent with previous ﬁndings showing
that activation of the AR by testosterone enhances growth
and differentiation and activates the mTORC1 pathway in
C2C12 myotubes.33,34 Nevertheless, the mechanistic link
between the AR and mTORC1 is not yet fully elucidated.
Our results suggest that AMPK is an intermediate in this
process. Indeed, mTORC1 is inhibited by AMPK, which itself
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Figure 5 Urolithin B (UroB) reduces denervation-induced skeletal muscle atrophy in mice. On Day 0, the left hindlimb of mice were denervated by
transecting the sciatic nerve and implanted with mini-osmotic pumps containing UroB, or vehicle DMSO. On Day 3 or 7, muscles were harvested under
anaesthesia. Muscles taken at Day 3 were used for analysing the signalling pathways, whereas those taken at Day 7 were used for weight and histo-
logical analyses. (A) For each mouse, the weight of the denervated muscle (DEN) was normalized to the weight of the innervated muscle (INN). Results
are expressed as the ratio DEN/INN (%). Data are means ± SEM from 10 mice per condition. P-values were determined with Student’s t-test. *P< 0.05,
**P < 0.01, and ***P < 0.001 vs. CTRL. (B) Azorubine staining of tibialis anterior (TIB) sections was used to quantify the area and the distribution of
ﬁbres. (C) Relative cross-sectional area of the TIB muscle. Data are means ± SEM from three mice per condition. ***P < 0.001 vs. CTRL INN; ££
£P < 0.001 vs. CTRL DEN. (D) Fibre size distribution. Data are expressed as the percentage of the total number of measured ﬁbres. (E) Effect of UroB
on plasma testosterone level after 3 or 7 days of denervation. Data are means ± SEM from ﬁve mice per condition after 3 days and 10 mice per con-
dition after 7 days of denervation. P-values were determined with Student’s t-test. ***P < 0.001 vs. CTRL. (F) Effect of UroB on FoxO1, FoxO3a, MAFbx
and MuRF1, and myostatin (mstn) mRNA levels, relative to β2-microglobulin level, after 3 days of denervation, as assessed by quantitative PCR. Data
are means ± SEM, n = 5 mice per condition. P-values were determined with two-way analysis of variance (ANOVA) and a Bonferroni post-hoc test.
**P < 0.01 and ***P < 0.001 vs. CTRL INN; $P < 0.05, $$P < 0.01, and $$$P < 0.001 vs. UroB INN; £P < 0.05 and £££P < 0.001 vs. CTRL DEN.
(G–H) Representative immunoblots and quantiﬁcation of the ubiquitinated proteins level. Data are means ± SEM, n = 5 mice per condition. P-values
were determined with two-way ANOVA and a Bonferroni post-hoc test. *P < 0.05 vs. CTRL INN. Data are means ± SEM, n = 5 mice per condition.
P-values were determined with two-way ANOVA and a Bonferroni post-hoc test. *P < 0.05 and ***P < 0.001 vs. CTRL INN; $P < 0.05 vs. UroB
INN. See also Supporting Information Figure S5.
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is regulated by the AR and testosterone35,36 as well as
urolithin B. The latter does not alter the energy status of
the cell as evidenced by unchanged nucleotide concentra-
tions and does not modify the phosphorylation state of liver
kinase B1, an AMPK activator. Although more data are re-
quired to highlight the mechanism by which urolithin B is
able to activate mTORC1, our results ruled out a mandatory
participation of Akt. High and low testosterone concentra-
tions seem to both activate mTORC1 but by an Akt-
dependent34 and an Akt-independent mechanism,25
respectively. Therefore, we do not exclude that Akt is acti-
vated by higher urolithin B concentrations than those used
in our experimental conditions in which we never observed
any change in Akt phosphorylation state. Moreover, PRAS40
does not seem implicated either. It has previously been
shown that the activation of mTORC1 by testosterone in
C2C12 myoblasts is independent of PRAS40 phosphoryla-
tion.25 This was corroborated by our results with urolithin B
(data are not shown). Data acquired in vivo support the role
of mTORC1 in the enhancement of protein synthesis induced
by urolithin B as the phosphorylation states of mTOR and
rpS6 were both increased.
As expected from the results on Akt, urolithin B did not
change the phosphorylation state of FoxO in vitro and after
a continuous perfusion of 3 days in the denervation experi-
ment. On the opposite, a long-term period of urolithin B
treatment (4 weeks) increases the phosphorylation of FoxO
suggesting an inhibition of protein degradation, possibly
mediated by kinases regulating FoxO activity independently
of Akt, like the serum glucocorticoid-regulated kinase 1
(SGK1) or AMPK. Moreover, urolithin B and insulin have no
additive effect on protein synthesis assessed by the SUnSET
method in fully differentiated C2C12 myotubes (data not
shown).
Testosterone is known to suppress the ubiquitin ligase-
mediated atrophy pathway to preserve muscle mass.37–39,34
Here again, our results support the idea that urolithin B
mimics the effects of testosterone as it decreased the mRNA
of the muscle-speciﬁc ligases MuRF1 and MAFbx and the
level of ubiquitinated proteins both in vitro and in denervated
muscles.
As the activation of mTORC1 was assessed by a number of
its downstream targets, an inhibition of autophagy was
expected. Contrary to our hypothesis, urolithin B did change
the autophagy markers neither in basal conditions nor in
autophagy-activated models. This suggests that the reduced
protein degradation observed in the presence of urolithin B
in C2C12 myotubes is probably due to an inhibition of the
ubiquitin–proteasome system rather than autophagy, which
remained unchanged.
Other potential mechanisms of action may involve the
anti-aromatase properties of urolithin B.26 The aromatase
enzyme is a cytochrome P450 CYP19A1 enzyme that is
responsible for catalyzing the reaction for the conversion of
testosterone into 17β-estradiol.40 Inhibition of aromatase
activity induces a higher plasma testosterone concentration
in rats,41 whereas urolithin B did not change the latter in
our mice. Consequently, it is unlikely that the anabolic prop-
erties of urolithin B are related to anti-aromatase activity. It
seems rather that urolithin B has ‘testosterone-like’ effects.
This hypothesis is supported by a lower mass of testicular
and epididymal adipose tissue in mice having received
urolithin B. Indeed, it is well established that the long-term
use of androgenic steroids affects the testis size in young
men42 and decreases body fat mass.43 However, our results
cannot support incontrovertibly the implication of ARs
in vivo, and clearly, further studies should carefully evaluate
the potential interest of urolithin B as a drug. Currently, the
dose–response and time–effect curves are unknown, and
possible side effects are numerous.
As urolithin B has ‘testosterone-like’ properties in vitro, we
decided to carry out a ﬁrst in vivo experiment in male mice
aiming to verify the enhancement of muscle growth. A sec-
ond study was dedicated to the protective effects of urolithin
B against muscle atrophy. For this experiment, we used a de-
nervation model in females because they are more sensitive
to muscle wasting. We found that urolithin B not only in-
duces muscle hypertrophy but also reduces denervation-
induced muscle atrophy in mice. Nevertheless, as the
in vitro results support a role of ARs, it is likely that these ef-
fects are gender-dependent and hence, could be larger in
males.
After 7 days of denervation, muscle mass was reduced by
11–29% depending on the muscle studied. SOL, a typical
slow-twitch muscle, showed the largest degree of atrophy.
When the mice received urolithin B, this atrophy was clearly
reduced in SOL, completely blunted in TIB, EDL, and QUA, but
not affected in GAS. Currently, we have no explanation re-
garding this lack of effect in GAS. However, a ﬁbre-type de-
pendent action of urolithin B may not be retained because
GAS is a mixed muscle, whereas EDL and SOL contain mostly
fast-twitch and slow-twitch ﬁbres, respectively.
It seems that the largest ﬁbres (>5000 μm2) were more
sensitive to denervation in control mice, whereas the
smallest ones (between 1000 and 2000 μm2) were more af-
fected in mice having received urolithin B. Although we have
no deﬁnitive explanations for this surprising result, it sug-
gests that urolithin B is less efﬁcient in the small size ﬁbres.
Moreover, 7 days of urolithin B treatment do not increase
the ﬁbre size in innervated muscle of female mice. Because
of the reduced number of ARs, one may not exclude that
urolithin B would be less efﬁcient in females.
As expected from previous studies,23,44–46 the ubiquitin–
proteasome and the lysosomal–autophagy pathways were
activated in TIB muscle 3 days after denervation. Our results
are in agreement with previous ﬁndings showing that an inhi-
bition of the ubiquitin–proteasome system reduces muscle
atrophy in a model of denervation in rats.47 Surprisingly,
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mTORC1 was activated 3 days after denervation in CTRL mice.
These results are in agreement with those obtained in other
studies,48,45 indicating that mTORC1 activation could be an
adaptive or compensatory mechanism following denervation.
However, in those studies, the inactivation of mTORC1 by
rapamycin did not rescue the atrophy phenotype, suggesting
that the activation of mTORC1 is essential to maintain the
activity of protein synthesis in serious situations of denerva-
tion. This activation is possibly the consequence of a high
ubiquitin–proteasome activity associated with the release of
a large amount of amino acids.45 In our context, this activa-
tion of mTORC1 was not found in mice treated with urolithin
B. Therefore, we postulated that, after 3 days of denervation,
ubiquitin–proteasome activity was not high enough to stimu-
late the mTORC1 pathway in the treated animals.
It has been shown that myostatin mRNA level is increased
during muscle atrophy.49 Our results corroborate this ﬁnding.
We also observed a lower induction of myostatin mRNA in
the presence of urolithin B. The reduction of about 20% of
myostatin mRNA level by urolithin B during denervation
represents an important additional effect participating to
the conservation of muscle mass, but it may not explain by
itself the protective effects of urolithin B. Indeed, a recent
study demonstrated that denervation-induced atrophy was
not reduced by myostatin inhibition.48
To conclude, we identiﬁed the ellagitannin-derived metab-
olite urolithin B as a regulator of skeletal muscle mass. This
study highlights the potential usefulness of urolithin B for




C2C12 murine skeletal muscle myoblasts (ATCC, Manassas,
VA, USA) were grown as described.50 After 4 days in differen-
tiation medium, the myotubes were treated with urolithin B
(15 μM), rapamycin (40 nM), testosterone (100 nM), or
bicalutamide (5 μM) for 24 h. Myotubes were also incubated
with insulin (100 nM) for 1 h (puromycin incorporation exper-
iment) or 24 h (immunoﬂuorescence experiment) before
harvesting. Dulbecco’s modiﬁed Eagle’s medium was
purchased from Invitrogen (Carlsbad, CA, USA); horse serum
and foetal calf serum were purchased from Hyclone (Thermo
Fisher Scientiﬁc, Waltham, MA, USA). Rapamycin and
bicalutamide were from Sigma-Aldrich (St Louis, MO, USA).
Immunoﬂuorescence assay and analysis
C2C12 myotubes were ﬁxed in PBS containing 4% paraformal-
dehyde and permeabilized with PBS 0.5% triton X-100. The
preparation was incubated with an anti-desmin primary anti-
body (1/100; Sigma-Aldrich) diluted in PBS/BSA for 1 h at
37°C then washed in PBS, followed by a 30 min incubation
with ﬂuorescein-conjugated anti-mouse (1/100; Interchim
Fluoprobes 488). Nuclei were stained with Hoechst (0.1 mg/
mL; Sigma). The slides were examined with an Axiovert 40
ﬂuorescent microscope (Carl Zeiss, Oberkochen, Germany).
To estimate myotube size, the diameter of at least 500
myotubes per condition in at least three independent cul-
tures was measured using the ZEN lite software (Carl Zeiss,
Oberkochen, Germany). The average diameter per myotube
was calculated as the mean of three measurements taken
along the length of the myotube. The fusion index is deﬁned
as the proportion of cells that contain three or more nuclei.
The fusion index was determined after 5 days of differentia-
tion by counting at least 1000 nuclei per condition and per
culture in three independent cultures.
Western blot
Proteins were extracted, and western blots were run as
described,51 see Supporting Information.
RNA extraction and quantitative real-time PCR
Total RNA extraction from myotubes was performed with
Trizol® (Invitrogen, Carlsbad, CA, USA), according to the man-
ufacturer’s instructions. The RNA quality and quantity were
assessed by Nanodrop® spectrophotometry. Reverse
transcription was performed with iScript cDNA synthesis kit
(Bio-Rad, Hercules, CA, USA) from 1 μg total RNA. Real-time
PCR experiments were performed using a MyIQ2
thermocycler (Bio-Rad). Melting curves were analysed to
ensure the speciﬁcity of the ampliﬁcation process. Target
genes were normalized using the reference gene RPL-19 (ri-
bosomal protein 19) or β2-microglobulin (for the in vivo de-
nervation experiment), see Supporting Information for
additional details.
Androgen receptor luciferase activity measurement
Androgen receptor activity was measured with dual-
luciferase reporter genes (Qiagen, Venlo, The Netherlands).
C2C12 myoblasts were transfected by nucleofection accord-
ing to the manufacturer’s instructions (Lonza formerly known
as Amaxa®, Cologne, Germany). C2C12 myoblasts (1.106)
were suspended in mouse nucleofector solution with 4 μg
of reporter or negative or positive control plasmids to ensure
the transfection efﬁciency. The myoblasts were then
nucleofected and cultivated as described earlier. The cells
were treated the 4th day of differentiation and harvested
the day after. For this purpose, the cells were lysed with
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passive lysis buffer (Promega, The Netherlands), and ﬁreﬂy
and renilla activities were measured using the dual-luciferase
kit (Promega). AR activity was assessed by normalizing the
ﬁreﬂy luciferase activity with the renilla luciferase activity.
In vivo models
Twelve-week-old male or female C57/Bl6 J mice (Janvier,
France) were housed in cages placed in a controlled environ-
ment (22–23°C, 14/10 h light/dark cycle). Mice were fed ad
libitum with the standard laboratory chow and used for
experiments within 3 weeks of their arrival. To ensure the
effect of urolithin B on skeletal muscle hypertrophy, male
mice were implanted subcutaneously with a mini-osmotic
pump (Alzet Model 2004, ALZA, CA, USA), which delivered
urolithin B (10 μg/day) or DMSO, continuously. After 28 days,
mice were injected intraperitoneally with 1 μM of puromycin.
Muscles, epididymal adipose tissue and testes were extracted
30 min after the injection. To assess the protective effects of
urolithin B against muscle atrophy, unilateral sciatic nerve
section was performed in female mice, and mini-osmotic
pumps were implanted (Alzet Model 2001, ALZA, CA, USA)
for delivering 10 μg/day urolithin B or DMSO. Three and
7 days after surgery, muscles from hindlimbs were removed.
Muscles from the non denervated limb served as a control.
All procedures used in this study were accepted by the com-
mittee for ethical practices in animal experiments of the
Université catholique de Louvain. The housing conditions
were in accordance with the Belgian Law of 29 May 2013
on the protection of laboratory animals (agreement number:
LA-1220548).
Histological analysis
Fresh tibialis muscles were collected, embedded with opti-
mal cutting temperature (OCT) medium, and immediately
frozen in isopentane cooled in liquid nitrogen. Transverse
sections (15 μm in thickness) were cut with a cryostat.
Sections were then stained with azorubine solution (1%)
to allow quantiﬁcation of ﬁbre number and area using
the imageJ software.
Statistical analysis
The results are expressed as means ± SEM. Statistical analy-
ses between urolithin B and control groups were performed
by Student’s t-test using Sigmaplot 12.5 software. When ex-
perimental designs included more than two experimental
conditions and one or two factors, a one-way analysis of var-
iance (ANOVA) or a two-way ANOVA was conducted after
testing standard assumptions. When a main effect was iden-
tiﬁed, Bonferroni post-hoc test was used to localize the
differences. Two-way ANOVA analyses were performed using
GraphPad Prism 6. The signiﬁcance threshold was set at a P-
value <0.05.
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Figure S1. Effect of urolithins A and B on the size and effect of
urolithin B on the energy status of C2C12 myotubes. (A and C)
After four days of differentiation, C2C12 myotubes were treated
with urolithin B, urolithin A or vehicle DMSO (CTRL) for addition-
ally 24 h. Cells were then ﬁxed and immunostained with anti-
desmin, nuclei were revealed by Hoechst staining. Scale bar
=50 μm. (B and D) Mean diameter of the myotubes seen in A
and C, respectively. Histograms are means ± SEM for 10 assays.
Independent cell cultures were carried out in triplicate. At least
2000 myotubes were analysed for both treated and untreated
cells. ***p < 0.001 vs CTRL cells (Student’s t-test). (E) Effect of
urolithin B (UroB, 15 μM) on the adenine nucleotides ratio in
C2C12 myotubes. (F) C2C12 myotubes were treated with
urolithin B (UroB, 15μM) for 24 h.Western blot analysis and rep-
resentative image for phosphorylated-LKB1. (G-H) C2C12
myotubes were treated with 15 μM urolithin B or 15 μM
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urolithin A or a vehicle DMSO. Representative image ofWB anal-
ysis for puromycin and eEF2, a stable protein in our samples.
Quantiﬁcation of the puromycin-labeled peptides, expressed as
a percentage of the values obtained in untreated CTRL cells. Data
aremeans ± SEM. P-values were determined by one-way ANOVA
with Bonferroni post-hoc test. ***p < 0.001 vs CTRL.
Figure S2. Urolithin B does not regulate autophagy in C2C12
myotubes. (A) Quantiﬁcation and representative immunoblots
of the ULK1 phosphorylation state at Ser757 and (B) the ratio
LCBII/?LC3BI. (C) Effect of urolithin B on Lc3b, p62 and
Gabarapl-1 mRNA levels, normalized to RPL-19 mRNA, as
assessed by qPCR. Incubation conditions: urolithin B (UroB-
15 μM), insulin (Ins-100 nM) and rapamycin (Rapa-40 nM). P-
values were determined by t-test. *p < 0.05, **p < 0.01,
***p < 0.001 vs CTRL
Figure S3. Positive and negative controls supporting the implica-
tion of the androgen receptor in enhancement of myotube
growth induced by urolithin B. (A-C) The androgen receptor
(AR) was inactivated in C2C12 myotubes by siRNA targeting the
receptor (siRNA AR). (A) mRNA level of AR in cells transfected
with a scramble (Scr) or siRNA, and treated or not with 15 μM
of urolithin B. (B-C) Myotubes were treated, during 24 h, with
100 nM insulin (Ins) as a positive control. (A) Representative im-
munoﬂuorescence images of myotubes, transfected with siRNA
AR or the scramble vector (Scr), and stainedwith anti-desmin an-
tibody and Hoescht. (B) Quantiﬁcation of myotube size. Data are
means ± SEM from 3 experiments, each with >300 myotubes
measured per condition. P-values were determined by two-
way ANOVA with Bonferroni post-hoc test. *p < 0.05,
**p < 0.01 vs Scr CTRL, ααp < 0.01 vs siRNA AR CTRL. (C-D)
The estrogen receptor 1 (ER1) was inactivated in C2C12
myotubes by siRNA targeting the receptor (siRNA ER1).
Myotubes were then treated during 24 h with either vehicle
DMSO or 15 μM urolithin B (UroB) or 100 nM testosterone (T)
used as a positive control. (C) Representative immunoﬂuores-
cence images of myotubes, transfected with siRNA targetting
the ER1 or Scr, and stained with anti-desmin antibody and
Hoescht. (D) Quantiﬁcation of myotube size. Data are means ±
SEM from 3 experiments, each with >300 myotubes measured
per condition. P-values were determined by two-way ANOVA
and a Bonferroni post-hoc test. *p < 0.05, **p < 0.01,
***p < 0.001 vs Scr CTRL; $$$p < 0.001 vs Scr UroB, ££
£p< 0.001 vs Scr T; ααp< 0.01, αααp< 0.001 vs siRNA ER1 CTRL.
Figure S4. Urolithin B increases puromycin incorporation in
soleus muscle. (A) Representative image of WB analysis
for puromycin, from SOL protein samples. (B) Quantiﬁca-
tion of the puromycin-labeled peptides in SOL muscle,
expressed as a percentage of the values obtained in the
control group. Data are means ± SEM from 6 mice per con-
dition. P-values were determined with Student’s t-test.
**p < 0.01, vs CTRL group.
Figure S5. Signaling associated with reduction of muscle
atrophy by urolithin B in mice. (A-F) Representative im-
munoblots and quantiﬁcation for total FoxO3a or phos-
phorylated FoxO1/?FoxO3a normalized to GAPDH
expression, for the ratio of phosphorylated Akt on total
Akt, for the ratio of phosphorylated AMPK on total
AMPK, for the ratio of phosphorylated mTOR on total
mTOR or for the ratio of phosphorylated rpS6 on total
rpS6. Data are means ± SEM, n = 5 mice per condition.
P-values were determined with two-way ANOVA with
Bonferroni post-hoc test. *p < 0.05 vs CTRL. (G) mRNA
level normalized to β2-microglobulin level and (H) pro-
tein level (representative immunoblot + quantiﬁcation)
for aromatase. Data are means ± SEM, n = 5 mice per
condition. P-values were determined with two-way
ANOVA and a Bonferroni post-hoc test. *p < 0.05,
**p < 0.01 and ***p < 0.001 vs CTRL group.
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